Thymoma Versus Thymic Carcinoma: Differences in Biology Impacting Treatment

Ronan J. Kelly, MD, MBA

Abstract
A better understanding of the biology of both thymomas and thymic carcinomas has occurred in recent years thanks to advanced technologies such as comparative genomic hybridization, expression array analysis, and next-generation sequencing. Gene expression profiling and genomic clustering studies have shown that thymic tumors as classified by the 2004 WHO system do have different molecular features. Because of the rarity of these tumors, there is a paucity of high-quality clinical research data, and treatment decisions are often guided by the small amount of prospective trial data, retrospective series, and individual case reports. The literature does report on several advanced thymic tumors that have responded to new targeted agents, indicating that across the spectrum of thymic malignancies there may be clinically relevant molecular subsets. Genomic profiling distinguishes type B3 thymoma and thymic carcinoma from type A and B2 thymomas. Furthermore, type B2 thymomas can be separated from other subgroups in that it has a more distinctly lymphocytic component than the other groups in which epithelial cells predominate. The presence of KIT mutations in thymic carcinomas rather than in thymomas further adds to a growing body of evidence showing that underlying tumor biology may in the future lead to molecular classifications, which may enhance therapies for these rare tumors. (JNCCN 2013;11:577–583)

Thymic epithelial tumors account for approximately 20% of all mediastinal tumors. Nevertheless, they are rare compared with other malignancies, constituting only 0.2% to 1.5% of all solid tumors.1 The WHO classification system distinguishes thymomas (types A, AB, B1, B2, and B3) from thymic carcinomas (type C) based on the morphology of epithelial tumor cells (with increasing degree of atypia along the spectrum from type A to C), proportion of lymphocytic involvement, and resemblance to normal thymic tissue. Clinically, these diseases can also present differently with a large variety of autoimmune disorders, including myasthenia gravis (30%) occurring in patients with thymoma, whereas patients with thymic carcinoma rarely if ever have autoantibody-induced phenomena.2 Surgery continues to be the most important therapeutic modality for early-stage disease, and a multidisciplinary approach incorporating surgery, radiation, and chemotherapy is recommended in advanced or recurrent disease. Research, however, has been hampered by the rarity of these tumors, which has led to a lack of international consensus surrounding appropriate histopathologic and staging criteria. Much debate has occurred regarding the limitations of the current histologic classifications with regard to both subtype definitions and consistency of diagnosis. The lack of established cell lines and animal models has hindered laboratory investigations, resulting in limited improvements in understanding of tumor biology. In the past decade, newer techniques such as comparative genomic hybridization (CGH), expression array analysis, and next-generation sequencing have resulted in incremental improvements in the understanding of these highly heterogeneous tumors. This article focuses on the biological differences between thymomas and thymic carcinomas that may impact treatment decisions, and discusses targeted therapy trials performed to date in the advanced disease setting.

From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Submitted February 19, 2013; accepted for publication April 10, 2013.
The author has disclosed that he has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Correspondence: Ronan J. Kelly, MD, MBA, The Bunting Blaustein Cancer Research Building, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room G93, Baltimore, MD 21231. E-mail: rkelly25@jhmi.edu
Staging and Pathologic Classification of Thymomas and Thymic Carcinomas

The most widely used system for staging thymic malignancies is the Masaoka staging system, which was originally developed in 1981 and focuses on the integrity of the thymic capsule, the presence of microscopic invasion into adjacent structures, and metastatic spread. The WHO histologic classification of thymomas and thymic carcinomas, first published in 1999 and updated in 2004, has helped alleviate some of the prior confusion caused by the presence of several previous classification systems. Types A, AB, and B1 have an excellent overall survival rate of greater than 90% to 95% at 10 years. Five-year survival for types B2 and B3 and thymic carcinoma are 75%, 70%, and 48%, respectively. Thymic carcinomas account for fewer than 1% of thymic malignancies and are much more aggressive tumors than thymomas. Clinically thymic carcinomas are more likely to metastasize to the liver, lymph nodes, and bones compared with thymomas, which rarely spread beyond the site of origin. Several subtypes of thymic carcinoma exist, including squamous cell, basaloid, sarcomatoid, mucoepidermoid, papillary, lymphoepithelioma-like, and undifferentiated carcinomas. Knowledge of the tumor biology underlying the different phenotypes between thymomas and thymic carcinomas has improved in recent years.

Immunologic Differences Between Thymomas and Thymic Carcinomas

In addition to differing clinically, thymomas and thymic carcinomas have distinctive immunologic, genetic, and molecular characteristics. Morphologic differences are outlined in the WHO classification, but immunohistochemical markers such as expression of major histocompatibility complex (MHC) class II or AIRE (autoimmune regulator gene) are becoming apparent. Approximately 30% to 40% of patients with thymoma develop an autoimmune condition, 50% of which will be myasthenia gravis. Unlike those with thymomas, patients with thymic carcinomas rarely develop autoantibody-induced phenomena. The molecular basis underlying defective AIRE expression in thymoma versus thymic carcinoma is not understood. The AIRE gene is located on chromosome 21q22.3 and is considered important for ectopic expression of peripheral self-antigen and for central thymic T-cell education and deletion of autoreactive clones. Patients with thymomas have higher rates of autoantibodies to cytokines than patients with thymic carcinomas, and also have a higher risk of developing second malignancies, most notably, non-Hodgkin’s lymphoma. A greater understanding of immunity and autoimmunity in thymoma is needed and may lead to future incorporation of immunotherapeutic strategies into treatment paradigms for thymomas.

Molecular Biology Differences Between Thymomas and Thymic Carcinomas

Cytogenetic studies have revealed chromosomal abnormalities in all histologic subtypes, including t(15;19) translocations and 6p22–p25 deletions. The most frequent genetic alterations identified across the spectrum of thymomas occur on chromosome 6p21.3 (MHC locus) and 6q25.2–25.3. Although thymic carcinomas are a distinct entity in the WHO classification system, they do share some similarities with type B3 thymomas, most notably in the gain of 1q and loss of chromosome 6. Additional data from CGH analysis performed on thymic carcinomas have demonstrated frequent copy number gains of 17q and loss of 3p, 16q, and 17p. The degree of genomic and recurrent copy number alterations increases from type A to type B3 and thymic carcinoma (Figure 1). Additional aberrations that have been described include multiple losses of genetic material and microsatellite instability in different chromosomes (3p22–24.3; 3p14.2 [FHIT gene locus]; 5q21 [APC gene]; 6p21; 6p21–22.1; 7p21–22; 8q11.21–23; 13q14 [RB gene]; and 17p13.1 [p53 gene]). In addition to the losses in the long arm of chromosome 6, the loss of heterozygosity (LOH) on chromosome 5 (5q21; APC gene) may be the most significant. Inoue et al. showed that alterations in chromosome 6 vary according to the WHO subtype (type A, 10%; type AB, 12%; type B, 20%–26%; thymic carcinoma, 35%) and with clinical stage at diagnosis (stage I, 7%; stage II, 27%; stage III, 21%; stage IV, 24%). In this study, the authors found genetic aberrations on chromosome 6 in 31 of 40 thymoma cases evaluated (77.5%), and these occurred in 5 separate hot spots. The most frequent LOHs (48.6%) occurred in region 6q25.2. Another hot spot showing LOH in 32.4% of tumors was located...
on 6q25.2–25.3. The third hot spot (30%) showing LOH appeared in region 6p21.31, including the MHC locus, and the fourth (26.3%) was detected on 6q14.1–14.3. Some tumors (21.6%) showed LOHs within a fifth hot spot on 6q21. Inoue et al. concluded that several tumor suppressor genes on chromosome 6 seem to be involved in the pathogenesis of thymoma. MSI has also been described on chromosome 6 in 10% of thymomas, more commonly in type B thymoma. Girard et al. performed array-based comparative genomic hybridization to identify potential recurrent copy number changes at the DNA level on 45 thymic tumor specimens. In this analysis, a hierarchical cluster algorithm revealed 2 major groups. Cluster 1 (n=19) was associated with thymic carcinoma and type B3 thymoma and was characterized by multiple chromosomal aberrations. Cluster 2 (n=26) was associated with type A and B2 thymomas and showed infrequent copy number alterations (P<.001; \( \chi^2 \) test). Interestingly, no association was seen between clinical stage and the presence of these genomic clusters. Further subdivision of cluster 1 was possible into cluster 1a (n=9) with only type B3 thymomas and thymic carcinomas, characterized by chromosome 1 gain, and cluster 1b (n=7) containing thymomas and thymic carcinomas sharing chromosome 6 loss. The group separately analyzed thymoma types A and B and thymic carcinoma to identify recurrent gene copy number alterations, but no significant results were identified.

In an effort to further understand the molecular biology of thymic malignancies and to progress beyond clinical and morphologic features, Badve et al. performed whole-genome gene expression analysis and correlated their findings with outcomes in 34 patients with thymoma. In this study, 10 patients had stage I disease, 12 had stage II, 6 had stage III, and 6 had stage IV, and all patients had surgery with curative intent. The tumors were categorized into group 1 (types A and B; n=9), group 2 (types B1 and B2; n=19), and group 3 (type B3; n=6). Unsupervised clustering of gene expression data identified 4 clusters of thymic tumors that showed significant correlation with histologic classification (P=.002). Neither histology nor clusters correlated with clinical outcome. As a result of significant differential expression (P<.01) with histologic groups in ANOVA analysis, the authors selected the top 15 upregulated and 15 downregulated genes to generate a supervised clustering heat map (Figure 2), indicating that gene expression analysis may separate these heteroge-
Focused Review

Kelly

neous tumors into separate clusters, which may have implications for future treatment strategies. In addition, the authors identified several genes associated with clinical behavior of thymic tumors, including stage, relapse, and metastasis, and some were confirmed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Among the top genes chosen, Aldo-keto reductase family 1 B10 (AKR1B10) and junctophilin-1 (JPH1) were upregulated in both stage III and IV disease. A hedgehog target gene, COL11A1, was downregulated in advanced-stage disease. AKR1B10 and JPH1 showed a 5.96-fold ($P=0.05$) and 3.01-fold ($P=0.18$) increase in metastasis-positive tumors compared with nonmetastatic disease, and COL11A1 was decreased 12.5-fold ($P=0.11$) in stage IV tumors. As a result of the differential expression levels of these genes, they were selected for validation by qRT-PCR, which confirmed the differential expression in the different phenotypes. These findings require external validation in independent cohorts of cases, but may in the future suggest potential therapeutic targets. The presence of identifiable genetic aberrations in thymic malignancies has stimulated interest in targeted therapy trials in an effort to improve treatments of advanced disease.

Targeted Therapy

Personalized medicine is applicable to rare tumors such as thymomas and thymic carcinomas. Several small studies and case reports have evaluated targeted therapies, and ongoing trials are evaluating genetic alterations that may be predictive or prognostic in thymic malignancies (Table 1).

KIT Pathway

KIT is differentially expressed in thymic malignancies, with immunohistochemistry positivity occurring in up to 73% to 86% of thymic carcinomas, but limited overexpression is seen in thymomas, with
only 2% demonstrating positivity.\textsuperscript{18,19} It was originally believed that this difference in tumor biology would lead to a clear difference in treatment strategies for thymic carcinomas versus thymomas because of the fact that KIT is a recognized target in other tumor types, most notably gastrointestinal stromal tumors. Unfortunately, despite the high frequency of KIT expression in thymic carcinomas, the rate of KIT mutations remains low at 7% to 9%. Four mutations have been described to date: the V560 deletion\textsuperscript{20} and L576P substitution,\textsuperscript{21} both found in exon 11; D820E mutation in exon 17\textsuperscript{22}; and the H697Y mutation found in exon 14.\textsuperscript{15}

A phase II trial evaluated imatinib in 7 patients with either type B3 thymoma (n=2) or thymic carcinoma (n=5). KIT expression was found in 1 of 4 samples on immunohistochemistry, and no mutations in c-KIT or platelet-derived growth factor receptor A (PDGFR-A) genes were demonstrated in 3 tumors examined. No responses were seen with imatinib therapy.\textsuperscript{23} Sunitinib may have activity in patients with thymic carcinoma harboring KIT mutations. Three of 4 patients experienced partial responses ranging from 2 to 18 or more months, and the other had prolonged stable disease lasting 22 months.\textsuperscript{24} Similarly, Girard et al\textsuperscript{15} showed that the H697 mutation is potently inhibited by both imatinib and sunitinib. Another case report documented disease activity in a patient with thymic carcinoma with a KIT D820E mutation (resistant to imatinib) treated with sorafenib, reporting a partial response in all metastatic sites and a progression-free survival of 15 months.\textsuperscript{22} Future decisions regarding the sensitivity of thymic carcinomas to KIT inhibitors will need to match the identified mutation to the correct targeted agent. Published sensitivities to date show that the V560 deletion and L576P substitution are sensitive to imatinib, the D820E mutation is sensitive to nilotinib, and the H697Y mutation is sensitive to sorafenib.\textsuperscript{16}

**Epidermal Growth Factor Pathway**

Unlike lung cancer, somatic activating epidermal growth factor receptor (EGFR) mutations are extremely rare in thymic malignancies, except for a few isolated case reports in Asian patients.\textsuperscript{21,25} EGFR protein overexpression on immunohistochemistry is present in approximately 70% of thymomas and 30% of thymic carcinomas.\textsuperscript{19,26} No correlation is seen between EGFR staining and thymoma histologic type. EGFR gene amplification with fluorescence in situ hybridization (FISH) occurs in approximately 20% of thymic malignancies, most notably in type B3 thymomas and thymic carcinomas, and is associated with more advanced stage and capsule invasion.\textsuperscript{27} A small study evaluated the efficacy of gefitinib, 250 mg daily, in 26 previously treated patients with metastatic thymoma (n=19) or thymic carcinoma (n=7),\textsuperscript{28} showing no complete responses, 1 partial response lasting 5 months, and 14 stable diseases. Median time to progression was 4 months. None of the tumors analyzed with DNA sequencing had evidence of EGFR or KRAS mutations. A second phase II trial evaluated the efficacy and safety of the combination of erlotinib and bevacizumab in 18 (thymoma, 11; thymic carcinoma, 7) pretreated patients with progressive malignant thymic tumors. Standard-dose erlotinib, 150 mg daily, and bevacizumab, 15 mg/kg intravenously
Histone Deacetylase Inhibitors

Histone deacetylase (HDAC) inhibitors have been evaluated in thymic tumors, most notably the pan-HDAC inhibitor belinostat, which demonstrated modest antitumor activity. In a phase I study of belinostat, a patient with thymoma experienced a minor response that lasted for 17 months on treatment. As a result, the authors performed a phase II trial, whereby belinostat was given through intravenous infusion at 1 g/m2 on days 1 through 5 of a 21-day cycle until disease progression. Forty-one patients were enrolled: 25 with thymoma and 16 with thymic carcinoma. Two partial responses in patients with thymomas (response rate, 8%; 95% CI, 2.2%–25%), 25 stable diseases, and 13 progressions were seen. No responses were seen in patients with thymic carcinomas.

Insulin-Like Growth Factor Pathway

The insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) has been identified as a poor prognostic indicator in thymic malignancies. Expression of IGF-1R does differ between thymomas (4%) and thymic carcinomas (37%), indicating a possible difference in tumor biology that may be targetable. In a retrospective analysis, IGF-1R expression was less in types A, AB, and B1 thymomas compared with types B2 and B3 and thymic carcinomas (P<.001). The authors performed a phase II study of cixutumumab, an IGF-1R monoclonal antibody in patients with previously treated advanced thymic tumors. No activity was demonstrable in thymic carcinomas; however, the results for activity in thymomas are awaited.

Conclusions

Tumors of the thymus are defined histologically by the 2004 WHO classification system; however, expression and genomic clustering results indicate that different molecular features exist across the spectrum of thymic tumors. Additionally, thymic carcinomas and type B3 thymomas do seem to be different from type A and B2 thymomas, indicating that a molecular classification may be more useful in future classification systems. The rarity of thymic malignancies has for years been seen as a hindrance in efforts to understand the biology of these tumors. Although large-scale phase III trials are not possible in advanced thymic malignancies, in the past decade researchers have begun to decipher the various molecular abnormalities that in the future may lead to more successful therapeutics. Although surgery continues to be the mainstay of treatment in operable cases, efforts are underway to develop genetic signa-
tutes in the clinically relevant subsets of thymomas and thymic carcinomas to determine which patients will need which treatment. The International Thy-mic Malignancies Interest Group is fostering greater international collaborations in an effort to improve the outcomes for patients in the years ahead.

References

18. Pan CC, Chen PC, Chiari H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202:375–381.